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Abstract
Background: Recent studies show the importance of interactions between CD47 expressed on acute myeloid leukemia
(AML) cells and the inhibitory immunoreceptor, signal regulatory protein-alpha (SIRPa) on macrophages. Although AML
cells express SIRPa, its function has not been investigated in these cells. In this study we aimed to determine the role of the
SIRPa in acute myeloid leukemia.
Design and Methods: We analyzed the expression of SIRPa, both on mRNA and protein level in AML patients and we
further investigated whether the expression of SIRPa on two low SIRPa expressing AML cell lines could be upregulated
upon differentiation of the cells. We determined the effect of chimeric SIRPa expression on tumor cell growth and
programmed cell death by its triggering with an agonistic antibody in these cells. Moreover, we examined the efficacy of
agonistic antibody in combination with established antileukemic drugs.
Results: By microarray analysis of an extensive cohort of primary AML samples, we demonstrated that SIRPa is differentially
expressed in AML subgroups and its expression level is dependent on differentiation stage, with high levels in FAB M4/M5
AML and low levels in FAB M0–M3. Interestingly, AML patients with high SIRPa expression had a poor prognosis. Our results
also showed that SIRPa is upregulated upon differentiation of NB4 and Kasumi cells. In addition, triggering of SIRPa with an
agonistic antibody in the cells stably expressing chimeric SIRPa, led to inhibition of growth and induction of programmed
cell death. Finally, the SIRPa-derived signaling synergized with the activity of established antileukemic drugs.
Conclusions: Our data indicate that triggering of SIRPa has antileukemic effect and may function as a potential therapeutic
target in AML.
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Introduction
Currently only one third of adult patients diagnosed with acute
myeloid leukemia (AML) can be cured despite aggressive
chemotherapy, and relapse rate is still high in these patients
[1,2,3]. Although the prognosis of pediatric AML patients is
better, the outcome remains relatively poor. With standard
induction chemotherapy, complete remission (CR) for newly
diagnosed pediatric AML is achieved on more than 80% of
patients, however, about 30–50% of these children relapse from
minimal residual disease (MRD) cells that apparently survived
chemotherapy [4,5,6]. Therefore, new treatment modalities for
AML are warranted.
Distinct morphological subgroups in French-American-British
(FAB) classification associate with different chromosomal rear-
rangements and acquisition of recurring genetic abnormalities; for
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example t(8;21))(q22;q22) and t(15;17))(q22;q21) create fusion
genes, AML/ETO and PML/RARa, which predominate in FAB
M2 and M3 AML subtypes respectively. These proteins are two of
the most common AML-associated oncofusion proteins, which in
total represent 20% of the AML occurrence [7]. The cytogenetic
rearrangement involved with t(8;21) disrupt genes that are
required for normal hematopoietic development, such as subunits
of core-binding factor [8]. Expression of the PML/RARa fusion
protein leads to a differentiation block at the promyelocytic stage
that can be relieved by all-trans-retinoic acid (ATRA). Studies on
AML/ETO and PML/RARa expressing cells have revealed that
aberrant signaling pathways are involved [9]. Insights into these
signaling pathways in AML at molecular level will pave ways for
new treatment modalities.
Signal regulatory protein alpha (SIRPa) is a transmembrane
receptor composed of 3 immunoglobulin-like domains in its
extracellular region and an intracellular domain containing
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) which
recruit and activate SHP-1 and SHP-2 [10,11]. SIRPa is
predominantly expressed on myeloid and neuronal cells [10]
and its activation has been implicated in regulation of different
cellular functions such as adhesion, migration, growth and
differentiation [12,13,14]. Despite restricted expression of SIRPa,
CD47, the natural ligand for SIRPa [15], is ubiquitously expressed
and interacts with the SIRPa extracellular region. This interaction
results in inhibition of phagocytosis by macrophages through
tyrosine phosphatase activation and inhibition of myosin accumu-
lation [16,17,18]. CD47 functions as a ‘‘don’t eat me’’ signal and
plays a key role in the programmed cell removal of abberant
versus normal cells [19]. Indeed, it was recently shown that CD47
is overexpressed on AML leukemic stem cells as compared to their
normal counterparts (hematopoietic stem cells) and this contrib-
utes to inhibition of phagocytosis and clearance of LSCs [20]. In
addition, blocking antibodies directed against CD47 promoted
phagocytosis as suggested through disruption of CD47-SIRPa
interaction and this enhanced tumor clearance in vivo [20,21,22].
These findings are in line with several studies, which reported
elimination of tumor cells by employment of CD47 blocking
antibodies [20,22,23,24,25,26,27].
Although SIRPa is known to be expressed by AML cells as well
[11,28], its function on these cells has not been identified.
Furthermore, previous studies were performed with antibodies
that not only recognized SIRPa, but also several of the related
molecules such as SIRPb1 and SIRPc. In the present study we
have examined the mRNA and protein expression of SIRPa in a
large cohort of AML patients and determined its relevance for
AML cell survival. We show for the first time that SIRPa ligation




At this moment no human agonistic SIRPa antibody is
available. However, a rat agonistic SIRPa antibody (ED9) was
generated in our laboratory [10,29], that is also commercially
available at Serotec (Oxford, UK). Such an agonistic antibody has
much higher affinity to rat SIRPa as compared to CD47-Fc
fragments [30,31], so the use of this agonistic antibody was
preferred for mechanistic studies and optimal SIRPa triggering.
To be able to exert an agonistic signal using the available rat
antibody, a chimeric construct of SIRPa was generated carrying
rat SIRPa extracellular domain and human transmembrane and
cytoplasmic region. The following monoclonal antibodies (mAb)
were used in this study: ED9 (anti-rat SIRPa; mouse IgG1 isotype)
was labeled with Alexa-633, which was obtained from Invitrogen
(Breda, The Netherlands). Considering the differences between rat
and human SIRPa, it is not likely that the ED9 agonistic antibody
cross-reacts with the human SIRPa [30,31]. For the experiments
in the current study we used a concentration of 10 mg/ml ED9
antibody. This concentration may be considered as relatively high,
but at this concentration the antibody is still specific since the
negative controls (i.e. empty vector cells) show no response to this
antibody at all. A dose-response curve is depicted in Figure S1.
Rabbit polyclonal Ab8120 (Abcam, Cambridge, United King-
dom) is directed to the cytoplasmic tail of human SIRPa. Mouse
anti-actin monoclonal antibody, mAb1501R, was purchased from
Chemicon International (Temecula, CA, USA). mAb against
caspase-3 was obtained from Cell Signaling Technology (Boston,
MA, USA). APC-labeled anti-human CD11b was acquired from
BD pharmingen (San Jose, CA, USA). PE- labeled B6H12 was
purchased from Santa Cruz Biotechnology and B6H12 F(ab’)2-
fragments were generated in our laboratory by pepsin digestion as
previously described [32].
The histone deacetylase (HDAC) inhibitors (Trichostatin A
(TSA), valproic acid (VPA) and sodium butyrate) and ATRA were
purchased from Sigma Aldrich (St Louis, MO, USA). 5-aza-2-
deoxycytidine (DAC, decitabine) was kindly provided by Pharma-
chemie BV (Haarlem, The Netherlands). Cytarabine (CytosarH)
was obtained from Pharmacia & Upjohn (Woerden, The Nether-
lands). Daunorubicin (CerubidineH) was purchased from Rhone
Poulenc Rorer (Amstelveen, The Netherlands). Etoposide (PV16,
VepesidH) was obtained from Bristol-Myers Squib (Woerden, The
Netherlands). Imatinib was provided by Novartis (The Nether-
lands). zVAD was obtained from Merk Biosciences (Darmstadt,
Germany).
Patient samples
For the expression array experiments bone marrow and/or
peripheral blood samples were collected from adult AML patients
at diagnosis, as described by Valk PJ et al. [33]. Bone marrow
and/or peripheral blood samples from children diagnosed with de
novo AML were collected from the following study centers: VU
University Medical Center, Amsterdam, The Netherlands; The
Dutch Childhood Oncology Group (DCOG), The Hague, The
Netherlands and the AML BFM-study Group, Hannover,
Germany. AML subtypes were classified according to the criteria
by Bennett et al., including the modifications to diagnose FAB
subtypes [34]. Mononuclear cells were isolated by density gradient
centrifugation as described previously [35]. All samples contained
at least 80% leukemic cells, as determined morphologically by
analyzing May-Gru¨nwald-Giemsa (Merck, Darmstadt, Germany)
stained cytospins.
Cell Lines and culture conditions
The human leukemic cell lines KG1a (primitive human
hematopoietic myeloid progenitor), Kasumi-1 (human acute
myeloid leukemia, FAB M2 t(8;21)), HL-60 (human promyelocytic
leukemia), NB4 (human acute promyeloctic leukemia, FAB M3
t(15;17)),U937 (human acute monocytic leukemia), THP-1
(human acute monocytic leukemia), CEM (human acute lympho-
blastic leukemia), Jurkat (human T-cell acute lymphoblastic
leukemia) were routinely cultured in RPMI 1640 medium (Gibco
Laboratories, Irvine, UK) supplemented with 10% fetal calf serum
(Integro BV, Dieren, the Netherlands). Kasumi-1 cells (0.56106)
were incubated for 0, 3, 24, 48, 72 and 96 hours with 1 mM DAC,
0.3 mM TSA, 0.5 mM VPA and 1 mM sodium butyrate in 5%
CO2 humidified air at 37uC. Cells were subsequently used for
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Western Blot analysis, as described below. Human neutrophils
were isolated from heparinized blood of healthy individuals by
centrifugation over isotonic Percoll (Pharmacia, Uppsala, Sweden)
and subsequent lysis of erythrocytes as described [36]. Neutrophils
were cultured in Hepes-buffered saline solution supplemented with
1% human serum albumin (Cealb: Sanquin, Amsterdam, the
Netherlands) and 5 mM glucose.
DNA isolation
Cell lines. 1–56106 of KG1a, Kasumi-1 and HL-60 cells
were resuspended in HIRT buffer (0.6% SDS, 10 mM Tris,
10 mM EDTA pH 8). Proteinase K was added and samples were
incubated at 50uC for 2 hours and subsequently at 37uC
overnight. Phenol: chloroform (1:1) was added and the solution
was mixed vigorously and centrifuged. The aqueous layer was
transferred into a tube and the phenol/chloroform extraction was
repeated. Following centrifugation, the aqueous layer was
removed and the DNA was precipitated by NaOAC/EtOH
(1:24), washed with 70% EtOH and resuspended in TE buffer.
DNA concentrations were measured with spectrophotometer
(Nanodrop, Isogen, The Netherlands).
Patient samples. DNA was isolated from cryopreserved
cytospins. A sterile swab and a drop of sterile water were used to
wipe the cells from the slides. The swab was transferred into buffer
(100 mM Tris, 10 mM NaCl, 5 mM EDTA, 1% SDS pH 9)
containing proteinase K and incubated overnight at 52uC. Tubes
were centrifuged and DNA was isolated as described above. For
the method of the bisulphate sequencing of the DNA see Methods
S1.
Western blot analysis
Cells were washed in PBS, centrifuged and the cell pellet was
lysed with Igepal lysis buffer (Sigma-Aldrich) containing protease
inhibitor cocktail (Roche). Whole cell lysates were clarified by
centrifugation and denatured in Laemmli’s sample buffer (Bio-rad
Laboratories, Hercules, CA, USA). After that cell lysates were
subjected to Western blot and membranes stained with primary
and secondary antibodies.
Construction of retroviral vectors and transduction of
Kasumi-1 cells
The rat-human SIRPa fusion construct (chSIRPa) was gener-
ated from cDNA and PCR fragments as follows: nucleotide 1–
1236 of the rat SIRPa cDNA [10] was fused to nucleotide 1230–
1509 of the human cDNA (prot. accession No: NM_080792). The
chSIRPa protein contains amino acids 1–412 (rat extracellular
domain) and amino acids 411–503 (human transmembrane and
cytoplasmic region) resulting in a total length of 505 amino acids,
including the signal sequence. The sequence of the construct was
confirmed by automated sequencing.
For retroviral transduction the chSIRPa construct was cloned
into the retroviral expression vector pLZRSpMBN-linker-IRES-
eGFP(NotI) [37]. The Phoenix-A packaging cell line [38] was
transfected with the retroviral construct containing chSIRPa or
empty vector (EV) containing eGFP by calcium-phosphate
transfection. After puromycin selection (Sigma-Aldrich, St Louis,
MO, USA), harvested virus supernatant [37] was used for
transduction of Kasumi-1 or NB4 cells. chSIRPa-expressing cells
were subsequently selected in several rounds by FACS sorting
(MoFlo,Dako Cytomation) on the basis of eGFP expression to
reach to .98% positive cells. Cell surface expression of chSIRPa
was determined by FACS analysis using the ED9 mAb, as
described below. FACS-sorted, mock-transduced cells containing
EV were used as controls in all experiments. Ectopic expression of
SIRPa and/or eGFP were regularly monitored and were found to
be stable for several months, with .90% positive cells.
Cell proliferation and programmed cell death
For cell proliferation assays cells were seeded in triplicate at
16105/ml concentration in 96-well plates and treated with 10 mg/
ml of the ED9 mAb where indicated and incubated for the
mentioned time points up to 7 days. For programmed cell death
(PCD) experiments, cells were seeded at 0.56106 cells/ml and on
days 1 and 3 PCD was measured by Annexin V-phycoerythrin
and 7-amino-actinomycin D (7-AAD) or DAPI double staining
according to the manufacturer’s protocol (BD Pharmingen, San
Jose, CA, USA). All analyses were performed on a FACS calibur
(BD Biosciences, San Jose, CA, USA). Cells positively stained with
Annexin-V and 7-AAD negative were considered to be early
apoptotic.
Growth inhibition studies
Growth inhibitory effects of chemotherapeutics in combination
with ED9 mAb were evaluated with the MTT-assay, as described
previously [39]. SIRPa and EV cells were incubated with 4
concentrations of cytarabine (ara-C) 2.5–0.002 mM, daunorubicin
(DNR) 18.0–0.005 mM, etoposide (VP16) 4.4–0.01 mM and
imatinib 520.005 mM in combination with one fixed concentra-
tion of the ED9 mAb (10 mg/ml); these experiments were done in
triplicate. Within each experiment all drugs were tested alone, as
well as in combination. Drug interactions between chemothera-
peutic drugs and ED9 mAb were studied by using the multiple
drug effect analysis of Chou and Talalay [40] (Calcusyn software,
Biosoft, Cambridge, UK) and antagonistic, additive or synergistic
interactions were determined. This method is commonly used in
many drug interaction studies [41]. The interactions are deter-
mined by Combination Index (CI) which indicates synergism
(CI,0.9), additivity (CI = 0.9–1.1) or antagonism (CI.1.1). In the
CI-FA plot the CI values.0.5 are evaluated and per experiment a
mean CI was calculated from FA values 0.5, 0.75 and 0.9. The
average CI (6 SD) of three experiments is given for each of the
combinations.
Statistical analysis
The statistical significance of measured differences in prolifer-
ation and PCD between the various conditions and cell
populations was determined using the paired Student’s t-test.
Calculations were performed using Graph-pad Prism and SPSS
software. Statistical analysis (Cox proportional hazards model;
reported p values corresponded to the Wald test) on overall
survival and event free survival was performed in SPSS software.
Survival distribution was compared with median SIRPa expres-
sion of the whole group.
Results
SIRPa mRNA expression in AML
The mRNA level in pediatric AML patients was analyzed in a
micro-array dataset containing 226 samples [42]. SIRPa mRNA
expression varied considerably among different AML patients
(Figure 1A). A clear association was observed between SIRPa
expression and AML FAB subtypes with the highest levels found in
the myelo-monocytic FAB M4/M5 subsets. The SIRPa expression
levels in myeloblastic leukemic blasts were relatively low in the
FAB M0–M3 subtypes. The M6 erythroid type of AML also
showed a low SIRPa expression. Comparing acute myeloid
leukemia cases with normal bone marrow, lower expression of
Role of SIRPa in Acute Myeloid Leukemia
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SIRPa was observed in immature AML subtypes (Figure 1A),
suggesting a myeloid differentiation stage-dependent expression,
which is in line with the high expression of SIRPa found on
normal monocytes and macrophages [10]. In particular, the
significant difference between M0–M3 and M4/M5 (p,0.001),
and the different expression distribution are depicted in Figure 1B.
Classifying pediatric samples based on karyotypes showed the
highest (p = 1.63610210) and lowest (p = 2.0561026) expression of
SIRPa in MLL-rearranged and t(8;21) subgroups, respectively
(Figure 1C). Since we only accessed one pediatric dataset, we
validated these findings in adult AML datasets [33,43,44] and
consistent with the pediatric results the highest level of SIRPa
expression was found in M4 and M5 subtypes as compared to the
immature groups such as FAB M0, M1, M2 and M3 (Figure S2).
In addition, karyotype classification of 285 AML patients in an
adult dataset [33], showed increased SIRPa expression in inv(16),
and MLL-rearrangement groups (depicted as clusters 5, 9 and 16)
in comparison to t(8;21) and t(15;17) AML (Figure S1B).
To examine whether SIRPa expression is correlated with
patient survival, we performed an analysis on overall survival (OS)
and event free survival (EFS) in the pediatric cohort (n = 175), for
which follow-up data are available. We observed that higher
SIRPa expression compared to the median of the 175 patients (8.1
arbitrary units), significantly correlated with unfavorable outcome.
Figure 1D shows the Kaplan Meier analysis based on OS (log-rank
p= 0.024, hazard ratio (HR) 1.7, p= 0.026). For EFS the data
were similar: log-rank p= 0.029, and HR: 1.5, p= 0.031. In
addition, following stratification on karyotype, we could not
generally find any significant relation between SIRPa and
outcome (not shown). Only within the MLL rearranged samples
a high SIRPa expression (above the median SIRPa expression of
the MLL rearranged group) exhibited a trend towards unfavorable
outcome (HR: 2.28, p = 0.062).
It is difficult to compare the outcome between children and
adults since the adults have, in general, a very dismal prognosis. In
the data set of Valk et al. [30] no association was found between
SIRPa expression and outcome on the whole cohort. For the adult
MLL rearranged samples, high SIRPa levels associated with a
slightly favorable outcome (HR: 0.84, p = 0.027). In both children
and adults, multivariate analysis reveals that SIRPa is not an
independent risk factor.
Recent studies have shown that CD47, the ligand for SIRPa, is
a prognostic factor in breast cancer and its expression correlates
with SIRPa expression in bone marrow and peripheral blood of
breast cancer patients [32,45]. We therefore evaluated a possible
association between SIRPa and CD47 expression in different
datasets [33,42,46], however we did not find any evidence for such
an association in AML. Figure 1E shows that CD47 is equally
distributed among the pediatric AML subtypes while there is a
clear difference in SIRPa expression with the MLL-rearranged
clustering in the high SIRPa range.
SIRPa protein expression in AML
We determined SIRPa protein expression, by Western blotting
using an antibody directed to the cytoplasmic tail of the human
SIRPa on various leukemic cell lines and patient samples. While
no expression was observed among acute lymphoblastic leukemia
(ALL) cell lines, AML cell lines differentially expressed the SIRPa
protein (Figure 2A). In particular, immature myeloblasts such as
t(8;21) Kasumi-1, KG-1, HL60 cells or promyelocytes like t(15;17)
NB4 cells expressed low or undetectable levels of SIRPa protein
compared to more differentiated monocytic cells such as THP-1
and U937 (Figure 2A). We also analyzed 20 primary pediatric
AML patient samples and consistent with the mRNA data, SIRPa
protein expression was low/undetectable in immature subgroups
compared to the more mature groups such as M4 and M5
(Figure 2B, C). As expected we did not observe SIRPa expression
in ALL patient samples (n = 10) (Figure S3). Collectively, these
findings suggest a selective myeloid and differentiation stage-
dependent expression of SIRPa mRNA and protein expression in
AML.
Upregulation of SIRPa upon differentiation of t(15;17)
AML cells
To address whether SIRPa expression is upregulated upon
differentiation of AML cells, we selected the NB4 cell line, a
t(15;17) M3 FAB subtype, which only express low levels of SIRPa
(Figure 2A). Since ATRA treatment of t(15;17) APL patients is
known to result in granulocytic differentiation [47,48], we
examined if SIRPa expression increased after exposure to ATRA.
To address this, the NB4 cells were incubated with 1 mM ATRA
for 7 consecutive days and granulocytic differentiation of the NB4
cells was confirmed by upregulation of the common myeloid
marker CD11b (Figure 3A). In concert with the increased
differentiation of NB4 cells, SIRPa protein expression was
markedly upregulated following ATRA exposure (Figure 3B).
This upregulation was already detectable after 24 hrs and it was
further increased during the following days of treatment.
Induction of programmed cell death in t(15;17) AML cells
following SIRPa ligation
Our initial experiments with the rat myeloid cell line NR8383
showed that several agonistic monoclonal antibodies [49] against
rat SIRPa (for example ED9, ED17 or OX41) or recombinant Fc-
fusion proteins containing the extracellular region of CD47, the
natural ligand of SIRPa, are able to suppress cell proliferation
(Figure S4). In order to investigate the effect of SIRPa ligation in
NB4 cells we tested a variety of previously reported antibodies
against SIRPa, but these either lacked the appropriate specificity,
showing cross-reactivity with other SIRP family members, or
lacked the agonistic activity [28,32]. In addition CD47-Fc did not
show a sufficiently high affinity for binding to SIRPa in our in vitro
experiments to be used as an agonistic (data not shown). Hence, to
be able to study the effect of SIRPa triggering in human myeloid
cells, we generated a chimeric SIRPa (chSIRPa) construct that
enabled the use of the rat specific SIRPa agonistic ED9 mAb. This
chSIRPa construct consisted of the extracellular region of rat
SIRPa and the transmembrane and the cytoplasmic domains of
human SIRPa [10]. Stable t(15;17) NB4 cell lines expressing
chSIRPa or empty vector (EV) were generated by retroviral
transduction. Flow cytrometric analysis of the retrovirally trans-
duced and FACS-sorted cells showed that the vast majority
(.90%) of cells had been transfected by chSIRPa (Figure 3C).
The levels of chSIRPa expression (i.e. mean fluorescence) were
comparable to those seen, with the same mAb, on rat
macrophages or granulocytes ([10] and data not shown).
Ligation of SIRPa in NB4 cells by agonistic ED9 mAb resulted
in induction of programmed cell death (PCD) as quantified by flow
cytometry using annexin-V/7-AAD staining (Figure 3C). After
24 h of exposure to ED9 mAb, the percentage of annexin-V
positive cells was significantly higher in the NB4 chSIRPa cells
(47.368.6%), as compared to NB4 EV cells (15.165.0%;
p= 0.009) (Figure 3C). These data support the requirement for
ED9 binding to SIRPa, since no induction of cell death was
observed in NB4 EV cells. These findings provide evidence for
induction of cell death capacity by SIRPa triggering in APL cells.
Role of SIRPa in Acute Myeloid Leukemia
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Figure 1. SIRPa mRNA expression and its prognostic effect in pediatric AML cohort. (A) SIRPa mRNA expression was determined in
different FAB subtypes. The dots represent individual patients and the horizontal bar is the group mean. The horizontal dotted line represents the
mean levels (139.6; n = 5) of SIRPa expression in normal CD34+ HSC. (ND: not determined). (B) Frequency of SIRPa expression among different FAB
subtypes of AML patients is shown as stacked histograms. (C) SIRPa mRNA expression as stratified after karyotype (NK: normal karyotype). (D) Overall
survival of pediatric AML patients (n = 175) stratified according to either low (, median of 8.1) or high ($ median 8.1) SIRPa mRNA expression. (E)
Correlation between CD47 and SIRPa mRNA expression is shown by the blue and red dots, respectively. The lower bar demonstrates the cluster of
patients in karyotypes, in which higher SIRPa expression is clustered in blue, representing the MLL rearrangement group on the right side.
doi:10.1371/journal.pone.0052143.g001
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From a therapeutic perspective, it would appear beneficial to
relieve differentiation block in M3 AML cells by using ATRA and
as a result to upregulate SIRPa expression, which can subse-
quently be targeted by an agonistic antibody to induce PCD.
Clearly prerequisite for such a strategy to be successful would be
the efficiency of SIRPa triggering following differentiation.
Therefore we examined whether apoptosis induction via SIRPa
persisted after differentiation with ATRA. Stably transduced NB4
(chSIRPa and EV) cells were exposed to 1 mM ATRA in
combination with the fixed concentration of 10 mg/ml ED9
mAb, which was shown to trigger PCD in the NB4 chSIRPa cells.
As expected, ATRA treatment alone did not have any effect on
PCD, whereas ED9 resulted in PCD in the chSIRPa transduced
NB4 cells and this was not significantly altered after differentiation
with ATRA. Furthermore while SIRPa triggering by ED9 mAb
does induce programmed cell death, we found that it did not affect
differentiation (Figure S5).
Taken together, these data indicate that ATRA provides a
stimulus for differentiation of t(15;17) APL cells and this results in
upregulation of SIRPa expression to a level that makes the cells
prone to cell death induction via SIRPa triggering even in
differentiated M3 cells.
Upregulation of SIRPa following differentiation of t(8;21)
AML cells
To examine whether the low endogenous expression of SIRPa
is also upregulated following differentiation of other low-SIRPa-
expressing myeloid leukemic cells, we selected t(8;21) Kasumi-1
cells. These cells belong to AML M2 FAB subtype and express low
endogenous levels of SIRPa (Figure 2A). It has been shown that
histone deacetylase (H-DAC)-inhibitors such as butyrate, valproic
acid (VPA) and trichostatin (TSA) and DNA methyltransferase
(DNMT)- inhibitors such as decitabine, induce granulocytic
maturation of t(8;21) acute myeloid leukemia cells [50,51,52,53]
(and data not shown).
Kasumi-1 cells were exposed to TSA, VPA,butyrate or
decitabine for indicated time points, which resulted in markedly
increased SIRPa levels (Figure 4). With all drugs, an increase in
SIRPa protein expression was detected as early as 3 hrs after
exposure and this expression reached maximal levels after
approximately 24 hrs. These data show that SIRPa is upregulated
following differentiation of Kasumi-1 cells.
An alternative explanation for the upregulation of SIRPa in
t(8;21) AML was that these inhibitors of epigenetic silencing had
acted directly on the SIRPa gene (accession number: NP-
542970.1), and in fact this seemed possible since a prominent
CpG island is present in the PTPNS1 promoter region. DNA
methylation in this region was explored in Kasumi-1 cells and four
t(8;21) AML patients by bisulphite DNA sequencing. Results
revealed actually very low levels of DNA methylation in the
promoter region (Figure S6). We also analyzed the SIRPA2p
pseudogene, in which abundant methylation was detected in the
corresponding region [49]. Taken together these data strongly
suggest that the increased level of SIRPa in t(8;21) Kasumi-1 cells
following demethylating agents is the result of differentiation.
Inhibition of proliferation and induction of PCD in t(8;21)
AML cells by SIRPa triggering
Since triggering SIRPa by agonistic ED9 mAb induced cell
death in t(15;17) NB4 cells, we extended our findings in t(8;21)
Kasumi-1 cells, stably transduced with chSIRPa or EV (Figure 5A).
The overexpression of chSIRPa in Kasumi-1 cells itself did not
affect the growth, however culturing Kasumi-1 chSIRPa cells in
the presence of the agonistic rat ED9 antibody caused a significant
inhibition of proliferation (Figure S7). In order to investigate
whether growth suppression triggered by chSIRPa ligation
coincided with an enhanced level of cell death induction, the
percentage of cell death was quantified by flow cytometry, using
Annexin V and 7-AAD staining (Figure 5B). Already 24 hours
after adding ED9 mAb the percentage of early dying cells, defined
as Annexin V positive, was significantly higher in the Kasumi-1
chSIRPa cells, as compared to Kasumi-1 EV cells, while addition
of an irrelevant antibody had no effect (Figure 5B, lower panel).
Similar results were observed on day 3 of treatment, at which
ligation with ED9 mAb had caused significant cell death in
Kasumi-1 chSIRPa cells (35.2615.3% versus 10.462.8% in
untreated control cells; p=0.02). All effects required ED9 binding
to chSIRPa, since no induction of cell death was observed in
Kasumi-1 EV cells.
We next investigated whether cell death induction in Kasumi-1
cells was involved caspase activity, which is often required for
PCD. First, we investigated activation of the effector caspase-3,
which can be measured by evaluating the appearance of the p17
caspase-3 cleavage product. As shown in Figure 5C triggering of
SIRPa in Kasumi-1 chSIRPa cells did not result in any detectable
caspase-3 cleavage, whereas this was detected upon culture of
freshly isolated neutrophils. Furthermore, incubation with the
universal inhibitor of caspases, zVAD (10 mM), did not affect
programmed cell death induction via SIRPa in Kasumi-1
chSIRPa cells whereas neutrophil apoptosis was zVAD sensitive
(results not shown). Collectively, these findings indicate a growth-
suppressive and caspase-independent mode of PCD induction via
SIRPa in t(8;21) AML.
To examine whether the observed effects of ED9 mAb in
Kasumi-1 cells, occur through blocking of CD47-SIRPa interac-
tions, we used the blocking anti-CD47 antibody B6H12. As shown
in Figure S8, induction of cell death by ED9 cannot be mimicked
by B6H12. This experiment shows at least that the pro-apoptotic/
growth regulatory effects that we report in this study are not simply
due to a blocking of cis or trans CD47-SIRPa interactions and are
more likely due to agonism of the ED9 antibody that was actually
also reported by us before in another context [54].
SIRPa ligation synergizes with conventional antileukemic
and targeted agents in t(8;21) and t(15;17) AML cells
Considering the potential of exploiting SIRPa targeting to
improve the treatment of AML patients, we examined the efficacy
of the ED9 mAb in combination with clinically relevant
chemotherapeutic agents used for the treatment of AML. NB4
chSIRPa and EV cells were exposed to cytarabine (ARA-C) and
daunorubicin (DNR) in combination with ED9 mAb. Survival was
monitored after 4 days using a range of chemotherapeutic drug
concentrations, which had shown appropriate dose response
curves in pilot experiments. We used a fixed concentration of
Figure 2. SIRPa protein expression in AML cell lines and patients. Western blot analysis was performed in (A) cell lines and (B) 20 pediatric
AML patient samples. b-actin staining was used as loading control. (C) SIRPa expression is quantified relative to b-actin expression.
doi:10.1371/journal.pone.0052143.g002
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ED9 mAb (10 mg/ml), which had been shown to promote PCD in
NB4 cells (Figure 6A). Co-incubation of NB4 cells stably
expressing chSIRPa with each of the two chemotherapeutics
and ED9 mAb resulted in synergistic effects (combination indexes
(CI) using standard calcusyn calculation were
CIDNR= 0.0.5960.04 and CIARA-C = 0.6060.2). No effect of
ED9 mAb was seen in the NB4 EV cells (data not shown).
In addition, Kasumi-1 chSIRPa and EV cells were exposed to
ARA-C, DNR, and VP16 in combination with ED9. Since the
Kasumi-1 cell line has been described to harbor an activating c-kit
mutation [55], we also tested ED9 in combination with the
tyrosine kinase inhibitor imatinib mesylate (Figure 6B). Similar to
the experiments with the NB4 cell line, this was tested using a 4-
day survival assay applying a range of drug concentrations, which
had shown appropriate dose response curves in pilot experiments,
and a fixed concentration of ED9 mAb (10 mg/ml). The leukemic
cell survival of Kasumi-1 EV and chSIRPa cells after incubation
with ED9 alone were 9862.4% and 8764.4%, respectively. Co-
incubation of Kasumi-1 SIRPa cells with each of the four anti-
leukemic drugs and ED9 resulted in synergism which was
indicated by a shift in the dose-response curve. By using the
standard Calcusyn calculations for combination effects, a syner-
gistic effect of ED9 incubation was observed for all applied
chemotherapeutic drugs (combination indexes (CI) include:
CIARA-C = 0.4660.32; CIDNR= 0.7460.06, CIVP16 = 0.5560.066
and CIImatinib = 0.7560.11) (Figure 6B).
Taken together, these results show that expression and ligation
of chSIRPa provide growth inhibitory effects in t(15;17) and
t(8;21) AML cells and this had a synergism with established anti-
leukemic drugs.
Discussion
Insights into the molecular pathogenesis of AML have paved
the way for new treatment strategies that specifically target gene
products implicated in induction of the leukemia. In the present
study we have investigated the role of SIRPa as a potential target
in the treatment of AML. By evaluating SIRPa mRNA levels in
both pediatric and adult cohorts of AML patients, we observed a
differential expression of SIRPa in AML subtypes. Interestingly,
high expression of SIRPa was observed in more mature AML
subgroups (M4 and M5) in comparison to immature subtypes,
normal bone marrow and CD34+ blast cells. There was
interpatient vairability of SIRPa expression between patients with
M4 or M5 subtypes, which is probably due to heterogeneity of
AML. Nevertheless, higher expression in mature subtypes is
consistent with a differentiation related expression of SIRPa.
Consistent with this, an upregulation of SIRPa was also observed
during differentiation of AML cell lines, which express low
endogenous levels of SIRPa.
The expression of SIRPa was not correlated to the expression of
its ligand CD47, which was ubiquitously expressed on the AML
blasts. This is consistent with a recent study performed by
Nagahara et al. who showed that increased expression of SIRPa
and CD47 was not correlated on breast cancer cell lines. However
a stronger correlation was observed in the bone marrow and
peripheral blood of breast cancer patients compared to normal
cases [45]. They suggest that such host factor characteristics may
have implications for prognosis of breast cancer. We also evaluated
mRNA levels of other related genes in the various datasets of
Figure 3. Upregulation of SIRPa upon differentiation of
t(15;17) NB4 cells and induction of cell death following its
triggering. (A) NB4 cells were exposed to 1 mM ATRA and granulocytic
differentiation of the cells was examined by cell surface expression of
the common myeloid marker, CD11b. (B) SIRPa protein expression,
determined by western blotting, is upregulated in ATRA-incubated NB4
cells. b-actin is used as a loading control. (C) Flow cytometric analysis of
chSIRPa surface expression is determined by using ED9 mAb in
transduced NB4 empty vector and chSIRPa expressing cells. (D) 24 hrs
following ED9 (10 mg/ml) incubation, the percentage of cell death in
chSIRPa and EV transduced NB4 cells was quantified by APC-Annexin V
and PE-7AAD FACS staining. (E) Percentage of apoptosis after exposure
to 1 mM ATRA is shown in combination with 10 mg/ml of ED9.
doi:10.1371/journal.pone.0052143.g003
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AML. No clear association was observed between CD47 and
SIRPa or different FAB subtypes or karyotypes. In our AML
study, the association between SIRPa and prognosis is not strong
and does not function as an independent factor. Galbaugh et al
showed that SIRPa mRNA was high in triple negative breast
cancer and related to an increased invasiveness of the tumor [56].
However, thus far there are no publications that show a clear
correlation between SIRPa expression and outcome, even for
breast cancer. The lack of differential expression of CD47 in our
study might be due to the fact that we investigated the bulk of the
AML cells and not the leukemic stem cells, for which it was
previously established that CD47expression is associated with poor
prognosis [20].
We demonstrate here for the first time, that SIRPa ligation
using agonistic monoclonal antibodies inhibits cell growth and
promotes cell death induction. Our results suggest that PCD via
SIRPa is caspase-independent. This mechanism of cell death
induction has been reported previously in the context of AML
[57], in which no involvement of caspases in cell death of an AML
cell line was observed upon treatment with chemotherapeutic
drugs. It should be noted that CD47 ligation also induces caspase-
independent PCD [57], and it would seem reasonable to assume
that this was due to a potential blocking of cis-interactions between
CD47 and SIRPa on AML, rather than to agonistic triggering of
both receptors. However, observations show that this was not
likely to be the case, since the effects on t(15;17) NB4 cells and
t(8;21) Kasumi-1 cells could not be reproduced using blocking
antibodies against CD47 (Alvarez et al, not shown). The actual
mechanism underlying the pro-apoptotic effect of SIRPa trigger-
ing is under investigation. Clearly, one obvious candidate to
mediate growth inhibitory signals, particularly in myeloid cells, is
the cytosolic tyrosine phosphatase SHP-1. Our preliminary
findings show that SHP-1 and also the related SHP-2 are in fact
abundantly expressed in fresh AML samples and in established
AML cell lines (data not shown). In rodent macrophage cell lines
the hematopoietic phosphatase SHP-1 can indeed be recruited
and activated upon triggering of SIRPa by its natural ligand
CD47, as well as by the agonistic antibody ED9 used herein [54].
It should be emphasized that while the survival and proliferation
of AML may not be directly regulated by CD47-SIRPa
interactions, there the in vivo life span of leukemic cells may well
be affected by them in another way. In particular, recent studies
have demonstrated that CD47 can act as an anti-phagocytic or so
called ‘‘don’t eat me’’ signal that prevents clearance of human
leukemic cells by macrophages in xenogeneic mouse models in vivo
[20,21]. Other ‘‘don’t eat me’’ signals such as CD200 have also
been shown to be upregulated in multiple tumors including AML
[58]. Leukemic stem cells appear to have higher levels of CD47
than normal CD34+ HSC cells and this could provide them with a
selective advantage for survival. In this study we show that other
signals such as SIRPa can be upregulated to encourage such don’t
eat me signals and subsequent evasion from programmed cell
removal [19,58]. It must be noted that CD47 signaling can also be
regulated through binding to its ligand, thrombospondin-1(TSP-
1). This CD47-TSP-1 interaction has been shown to inhibit
response to nitric oxide and correspondingly increase radiosensi-
tivity. As a result, blocking such interactions could confer
therapeutic radioprotection of normal tissues [59,60,61].
Analysis of AML patients had revealed that higher levels of
CD47 are associated with a poor prognosis [17,18]. While the
results of these studies indicate that blocking of the interaction
between CD47 and SIRPa may be of interest from a therapeutic
perspective, our current results suggest that it may, perhaps even
simultaneously be beneficial to trigger SIRPa as well. Especially
since targeting the CD47–SIRPa phagocytic pathway alone is
likely to have toxic effects [58]. In fact, the ED9 antibody against
SIRPa that we have used herein appears both capable of
triggering programmed cell death as well as to block CD47-
SIRPa interaction [62]. Clearly, future studies are needed to
Figure 4. SIRPa upregulation in t(8;21) Kasumi-1 cells following treatment with inhibitors of epigenetic gene silencing. Kasumi-1 cells
were incubated with 1 mM Decitabine, 0.5 mM valproic acid, 1 mM Butyrate and 300 nM Trichostatin. Endogenous SIRPa protein level, determined by
Western blotting was upregulated at indicated time points. b-actin staining was used as a loading control.
doi:10.1371/journal.pone.0052143.g004
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generate the suitable agents that can trigger apoptosis via human
SIRPa and validate it as a potential treatment target in AML.
Supporting Information
Figure S1 Dose-response curve of ED9 antibody in-
duced apoptosis in Kasumi-1 cells. EV=kasumi cells
tranduced with empty vector, WT=kasumi cells tranduced with
wild type SIRPa. Apoptosis was measured after exposure to a
range of ED9 antibody concentrations. 10 mg/ml was selected as
optimal concentration for further studies. At this concentration no
effect was seen on cells only expressing the (human) constitutive
SIRPa.
(PPT)
Figure S2 SIRPa mRNA expression in adult AML
cohort. (A) SIRPa mRNA expression was determined in different
FAB subtypes of 285 adult patients. The dots represent individual
patients and the horizontal bar is the mean of the group (ND: not
determined). (B) Adapted correlation view of the 16 unsupervised
clusters (indicated on the left) of 285 adult AML specimens
identified by mRNA profiling [33], including the expression levels
of SIRPa using 3 independent probes on the right diagonal axes.
SIRPa expression is high in clusters 5, 9 and 16, but low in most
other clusters, including clusters 12 and 13, which contain almost
exclusively t(15;17) and t(8;21) AML, respectively.
(PPT)
Figure S3 SIRPa is not expressed in ALL patient
samples. Analysis of protein expression of SIRPa in pediatric
ALL patient samples by western blotting showed that SIRPa is not
expressed in these samples. b-actin staining was used as a loading
control.
(PPT)
Figure S4 Triggering SIRPa in the rat NR8383 macro-
phage cell line inhibits proliferation. NR8383 cells were
incubated for 18 hours with CD47-Fc protein or indicated anti-rat
SIRPa monoclonal antibodies (ED9, ED17 or OX41). 3H-
thymidine was added for 4 hours and proliferation was deter-
mined by incorporated radioactivity.
(PPT)
Figure S5 NB4 cells differentiate by ATRA exposure.
Differentiation of NB4 cells stably expressing chSIRPa and EV
was examined by flow cytometry after treatment with ATRA or
ED9. increased expression of CD11b was observed only after
ATRA but not by ED9 treatment.
(PPT)
Figure S6 PTPNS1 promoter region is not methylated.
Each circle indicates a CpG dinucleotide (open circles: unmethy-
lated, filled circles: methylated) and each line represents analyses of
a single amplified clone. SIRPa2p pseudogene, which is highly
highly homologous to PTPNS1 was used as a positive control with
high degree of methylation [49]. Methylation specific PCR and
bisulphate sequencing [63] of the Kasumi-1 cell line and four
Figure 5. Ligation of chSIRPa induces caspase 3-independent PCD in Kasumi-1 cells. (A) Flow cytometric analysis of SIRPa expression was
performed by using ED9 mAb in stable Kasumi-1 cells expressing chSIRPa and EV. (B) Kasumi-1 chSIRPa and EV cells were incubated with 10 mg/ml
ED9 mAb and the percentage of cell death was determined after 24 hrs. Annexin V and 7-AAD FACS staining defined that ligation of chSIRPa resulted
in increased cell death in chSIRPa Kasumi-1 cells compared to EV control cells. Data are means 6 SD calculated from 3 independent experiments
using triplicate samples (*: significant difference p,0.05). (C) Kasumi-1 cells expressing chSIRPa or EV were treated with 10 mg/ml ED9 for mentioned
time points. Caspase 3 staining shows no cleavage of the p32 subunit. As a positive control for caspase 3 cleavage, human neutrophils (PMN) were
incubated at room temperature for 0 and 24 hours.
doi:10.1371/journal.pone.0052143.g005
Figure 6. SIRPa-derived signal synergizes with different
antileukemic drugs. Inhibition of cell growth is depicted by
combination of ED9 mAb (10 mg/ml) with (A) Ara-C and DNR in NB4
cells expressing chSIRPa (B) Ara-C, DNR, VP16, DAC and imatinib in
Kasumi-1 cells expressing chSIRPa. Results are based on means of 3
experiments and are calculated using Calcusyn.
doi:10.1371/journal.pone.0052143.g006
Role of SIRPa in Acute Myeloid Leukemia
PLOS ONE | www.plosone.org 11 January 2013 | Volume 8 | Issue 1 | e52143
t(8;21) AML patients did not reveal methylation of the PTPNS1
promoter region.
(PPT)
Figure S7 SIRPa ligation results in inhibition of prolif-
eration in Kasumi-1 cells. Kasumi-1 cells expressing chSIRPa
or EV, were incubated with ED9 mAb for 7 days and cell
proliferation was evaluated by daily cell counting. Data are means
6 SD calculated from 3 independent experiments using triplicate
samples.
(PPT)
Figure S8 Blocking anti-CD47 antibody cannot mimic
ED9 effects in Kasumi-1 cells. (A) Flow cytometry data of
DAPI and Annexin-V staining and (B) Summary graph illustrates
the quantified flow cytometric data. Kasumi-1 cells expressing
chSIRPa or EV were incubated with ED9 mAb or B6H12 as
blocking anti-CD47 antibody. Percentage of cell death was
increased significantly in the case of ED9 treatment compared to
EV but B6H12 anti-CD47 incubation did not have this effect.
(PPT)
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